Epigenetic Inactivation of the Potential Tumor Suppressor Gene FOXF1 in Breast Cancer

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cancer Research (Impact Factor: 9.28). 07/2010; 70(14):6047-58. DOI: 10.1158/0008-5472.CAN-10-1576
Source: PubMed

ABSTRACT The expression of several members of the FOX gene family is known to be altered in a variety of cancers. We show that in breast cancer, FOXF1 gene is a target of epigenetic inactivation and that its gene product exhibits tumor-suppressive properties. Loss or downregulation of FOXF1 expression is associated with FOXF1 promoter hypermethylation in breast cancer cell lines and in invasive ductal carcinomas. Methylation of FOXF1 in invasive ductal carcinoma (37.6% of 117 cases) correlated with high tumor grade. Pharmacologic unmasking of epigenetic silencing in breast cancer cells restored FOXF1 expression. Re-expression of FOXF1 in breast cancer cells with epigenetically silenced FOXF1 genes led to G(1) arrest concurrent with or without apoptosis to suppress both in vitro cell growth and in vivo tumor formation. FOXF1-induced G(1) arrest resulted from a blockage at G(1)-S transition of the cell cycle through inhibition of the CDK2-RB-E2F cascade. Small interfering RNA-mediated depletion of FOXF1 in breast cancer cells led to increased DNA re-replication, suggesting that FOXF1 is required for maintaining the stringency of DNA replication and genomic stability. Furthermore, expression profiling of cell cycle regulatory genes showed that abrogation of FOXF1 function resulted in increased expression of E2F-induced genes involved in promoting the progression of S and G(2) phases. Therefore, our studies have identified FOXF1 as a potential tumor suppressor gene that is epigenetically silenced in breast cancer, which plays an essential role in regulating cell cycle progression to maintain genomic stability.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer-specific alterations in DNA methylation are hallmarks of human malignancies; however, the nature of the breast cancer epigenome and its effects on metastatic behavior remain obscure. To address this issue, we used genome-wide analysis to characterize the methylomes of breast cancers with diverse metastatic behavior. Groups of breast tumors were characterized by the presence or absence of coordinate hypermethylation at a large number of genes, demonstrating a breast CpG island methylator phenotype (B-CIMP). The B-CIMP provided a distinct epigenomic profile and was a strong determinant of metastatic potential. Specifically, the presence of the B-CIMP in tumors was associated with low metastatic risk and survival, and the absence of the B-CIMP was associated with high metastatic risk and death. B-CIMP loci were highly enriched for genes that make up the metastasis transcriptome. Methylation at B-CIMP genes accounted for much of the transcriptomal diversity between breast cancers of varying prognosis, indicating a fundamental epigenomic contribution to metastasis. Comparison of the loci affected by the B-CIMP with those affected by the hypermethylator phenotype in glioma and colon cancer revealed that the CIMP signature was shared by multiple human malignancies. Our data provide a unifying epigenomic framework linking breast cancers with varying outcome and transcriptomic changes underlying metastasis. These findings significantly enhance our understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers for this common malignancy.
    Science translational medicine 03/2011; 3(75):75ra25. DOI:10.1126/scitranslmed.3001875 · 14.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We previously identified FOXF1 as a potential tumor suppressor gene with an essential role in preventing DNA rereplication to maintain genomic stability, which is frequently inactivated in breast cancer through the epigenetic mechanism. Here we further addressed the role of the p53-p21(WAF1) checkpoint pathway in DNA rereplication induced by silencing of FOXF1. Knockdown of FOXF1 by small interference RNA (siRNA) rendered colorectal p53-null and p21(WAF1)-null HCT116 cancer cells more susceptible to rereplication and apoptosis than the wild-type parental cells. In parental HCT116 cells with a functional p53 checkpoint, the p53-p21(WAF1) checkpoint pathway was activated upon FOXF1 knockdown, which was concurrent with suppression of the CDK2-Rb cascade and induction of G(1) arrest. In contrast, these events were not observed in FOXF1-depleted HCT116-p53-/- and HCT116-p21-/- cells, indicating that the p53-dependent checkpoint function is vital for inhibiting CDK2 to induce G(1) arrest and protect cells from rereplication. The pharmacologic inhibitor (caffeine) of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) protein kinases abolished activation of the p53-p21(WAF1) pathway upon FOXF1 knockdown, suggesting that suppression of FOXF1 function triggered the ATM/ATR-mediated DNA damage response. Cosilencing of p53 by siRNA synergistically enhanced the effect of FOXF1 depletion on the stimulation of DNA rereplication and apoptosis in wild-type HCT116. Finally, we show that FOXF1 expression is predominantly silenced in breast and colorectal cancer cell lines with inactive p53. Our study demonstrated that the p53-p21(WAF1) checkpoint pathway is an intrinsically protective mechanism to prevent DNA rereplication induced by silencing of FOXF1.
    Cellular Signalling 09/2011; 24(1):316-24. DOI:10.1016/j.cellsig.2011.09.017 · 4.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We present a method for prognostics biomarker mining based on a genetic algorithm with a novel fitness function and a bagging-like model aver-aging scheme. We demonstrate it on publicly available data sets of gene expres-sions in colon cancer tissue specimens and assess the relevance of the discov-ered biomarkers by means of a qualitative analysis. Furthermore, we test per-formance of the method on the cancer recurrence prediction task using two in-dependent external validation sets. The obtained results correspond to the top published performances of gene signatures developed specially for the colon cancer case. 1 Background The recent advances in high-throughput technologies have opened a wide space of opportunities for studying complex diseases, such as cancer, at the molecular level. These led to the successful development of clinically approved diagnostic tests based on gene expression, such as the MammaPrint [1-2] for breast carcinoma. However, the complexity of resulting data from next generation sequencing or microarray ex-periments still poses a great interpretational challenge. High dimensionality that characterizes high-throughput data, together with usually low number of available samples, renders classical statistical methodology nearly helpless when faced with analytical tasks in this domain. This creates the increasing demand for data-driven modelling approaches capable of facilitating search for prognostics biomarkers. In this study we propose a methodology for mining cancer biomarkers from high-throughput data and demonstrate it on microarray samples in colon cancer. Colorectal cancer is the third most common cancer type worldwide [3]. The disease starts as a benign polyp that develops to advanced adenoma and finally to invasive carcinoma. Although fairly curable if discovered on time (prior to stage III), a long term survival of initially successfully treated colorectal cancer patients critically
    PRIB2012; 01/2012